Duke logo

ABBvie for Early Alzheimer's Disease - Clinical Trial

What is the Purpose of this Study?

We are doing this study to to test a new drug to learn if it can slow down Alzheimer's Disease when recognized very early.

What is the Condition Being Studied?

Mild Cognitive Impairment

Who Can Participate in the Study?

Adults ages 55 to 85 diagnosed with Mild Cognitive Impairment

Age Group
Adults

What is Involved?

If you participate in this study you will:
- Have screening tests to make sure it is safe for you to be in the study (physical and neurological exam, memory testing, questionnaires, and other procedures as needed)
- Be randomized (like drawing numbers from a hat) to get:
-- A study drug called ABBV-8E12 or
-- Placebo (an inactive substance like salt water or a sugar pill)
(you will have a 3 in 4 chance of getting the study drug and a 1 in 4 chance of getting placebo)
Neither you nor your study doctor will know whether you are getting the study drug or the placebo but they can find out in an emergency.

You will need to have a partner who will come with you during study visits and give independent information about how you are doing during the study.

You'll be in the study for about 2 years

Study Details

Full Title
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease
Principal Investigator
Protocol Number
IRB:PRO00075628
NCT:NCT02880956
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698